drugset / Trial / NCT00095186
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if orally-administered recombinant human lactoferrin is effective in the treatment of advanced renal cell carcinoma (RCC) in patients who have failed at least one prior systemic therapy for RCC.
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Human Lactoferrin | Protein / enzyme biologic | 1.5 g | Oral |